Press Release

Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank

by
Aspen Neuroscience Logo Icon

SAN DIEGO Calif., December 21, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed.“We are pleased to work with Silicon Valley Bank. … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer

by
Kim Raineri, CTO

SAN DIEGO, Oct. 19, 2022 – Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company’s executive team.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene on the Mesa

by
Xiaokui Zhang, PhD

SAN DIEGO, Oct. 11, 2022 — This week Xiaokui Zhang, Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif. including presenting a live corporate update and participating in a panel session to highlight new developments in the induced pluripotent stem cell (iPSC) field. This … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting

by
Aspen Roy IMG 5026 Final Square scaled

SAN DIEGO, June 22, 2022 — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A Bioinformatics-based Tool for Quality Control of iPSC-derived Dopamine Neuron Precursors for Transplantation,” featured the advanced … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners

by
Aspen Neuroscience Series B

Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease FOR IMMEDIATE RELEASE CONTACT:Angelyn Lowemedia@aspenneuro.com SAN DIEGO, Calif., May 9, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease

by
Human head with puzzle pieces

SAN DIEGO, Calif., April 12, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies, including the first autologous neuron replacement for Parkinson’s disease (PD), announced that this month it will launch the first patient screening study of its kind, working with multiple clinical screening sites in the … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer

by
Xiaokui Zhang, Phd

SAN DIEGO, Calif., November 18, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company’s executive team. With 20 years of progressive biopharmaceutical industry … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer

by
Kameel D. Farag

SAN DIEGO, Calif., Nov. 9, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company’s executive team

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President

by

SAN DIEGO, July 12, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Ana Sousa has joined the company as senior vice president of regulatory affairs and quality, and as a member of the company’s executive team. “Ana’s extensive regulatory … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Caryn Peterson Joins ASPEN Neuroscience Board of Directors

by

SAN DIEGO, June 22, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Caryn Peterson, executive vice president of Regulatory Affairs for Gossamer Bio, has joined the Aspen Board of Directors.  “We welcome Caryn as an important addition to our … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved